Ranbaxy’s Mohali SEZ Facility begins export of Atorvastatin to US market

02 Apr 2012 Evaluate

Ranbaxy Laboratories has commenced exports of Atorvastatin Calcium Oral Tablets to the US market, from its Mohali SEZ manufacturing facility, located in Punjab, India. The first consignment of Atorvastatin Tablets has been dispatched to the US market in March 2012. The supply of Atrovastatin tablets from India supplements the company’s current production from Ohm Laboratories Inc, USA.

Ranbaxy’s dosage facility at Mohali was approved by the US Food and Drug Administration (USFDA) in October 2011. Thereafter, in the first quarter of 2012, the company received approval from the USFDA to manufacture and market Atorvastatin 10mg, 20mg, 40mg and 80mg tablets. Earlier, international regulatory authorities such as the WHO-Geneva, National Medicine and Medical Devices Agency (NMMDA) - Romania, ANVISA- Brazil, TGA- Australia, Canada Health-Canada etc. had also approved the company's Mohali facility.

The new facility at Mohali will manufacture oral solid products for export to US, EU and other countries based on filings and after receiving the necessary approvals. It is equipped with the latest state-of-the-art technology, designed to meet global and local regulatory requirement and conforms to cGMP standards.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×